[external] APP raising heparin prices amid higher costs - Reuters - Fri 4:13 am
NEW YORK, May 15 (Reuters) - APP Pharmaceuticals Inc , the main supplier of the blood thinner heparin to the U.S. market in the wake of a contamination scandal, said on Thursday it was raising prices because of higher costs for raw materials, additional testing and labor.

[external] Bird flu pandemic seen needing multiple drugs - Reuters - Thu 9:00 am
LONDON, May 14 (Reuters) - Governments need to stockpile different sorts of flu drugs -- not just Roche Holding AG's Tamiflu -- to counter the danger of resistance in a pandemic triggered by bird flu, British experts said on Wednesday.

[external] Health ministers to debate drug patent dispute - Reuters - Thu 5:01 am
GENEVA, May 14 (Reuters) - Health ministers from around the world will try next week to bridge differences over how to overhaul drug patent rules that developing countries say make life-saving medicines costly and inaccessible.

[external] Japan cancels purchase of unsafe Australian barley - Reuters - Thu 4:45 am
TOKYO, May 14 (Reuters) - Japan cancelled the purchase of 20,000 tonnes of Australian food barley after the shipment was found to contain too much pesticide, Japanese health and farm ministries officials said on Wednesday.

[external] Kroger to expand discount drug program - Reuters - Wed 8:30 am
NEW YORK, May 13 (Reuters) - Supermarket operator Kroger Co said on Tuesday that it was expanding its generic drug program to include discounted bulk supplies and more women's medications.

[external] Kroger says to expand discount drug program - Reuters - Wed 7:10 am
NEW YORK, May 13 (Reuters) - U.S. supermarket operator Kroger Co said on Tuesday its in-store pharmacies will expand their generic drug program -- offering many 90-day prescriptions for $10.

[external] US doctors miss chances to give flu vaccines - Reuters - Tue 12:31 pm
WASHINGTON, May 12 (Reuters) - Doctors are missing plenty of opportunities to vaccinate people against influenza every year, flu shot maker Sanofi-Pasteur said on Monday.

[external] Forest ends promotion of Daiichi hypertension drug - Reuters - Tue 6:11 am
NEW YORK, May 12 (Reuters) - Forest Laboratories Inc has ended its agreement with Daiichi Sankyo Co Ltd to co-promote Daiichi's blood-pressure drug Azor, as Forest shifts resources to support other products, the companies said on Monday.